SecBot SecBot
8-K ·Filed May 5, 2026

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-206420
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a standard corporate update. Key catalyst to watch is the PDUFA date for MAPLE-HCM sNDA on November 14, 2026. Monitor prescription growth trajectory for MYQORZO as a leading indicator of commercial traction.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$74.84
T+0 close · May 5, 2026 · via day close
Latest settled
+3.06%
T+60 · $77.13
Vs SPY
+1.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $74.84entry
  2. T+1 · 6mo ago 0.00%α +0.33% · $74.84
  3. T+5 · 6mo ago −0.04%α −1.17% · $74.81
  4. T+20 · 6mo ago −5.52%α −8.30% · $70.71
  5. T+60 · 4mo ago +3.06%α +1.00% · $77.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (aficamten) for oHCM, positive ACACIA-HCM trial results for nHCM, and pipeline advancement. The filing is routine with no new material events or financial disclosures beyond previously announced data and launch metrics.

Key Facts

  • Cash, cash equivalents and investments of approximately $1.1B as of 3/31/26
  • MYQORZO launched in U.S. and China in January 2026; EU approval secured
  • 680 patients prescribed MYQORZO as of 3/31/26, growing to 1,100 as of 4/30/26
  • 1,400+ REMS-certified HCPs as of 3/31/26; average 2.4 prescriptions per HCP
  • sNDA for aficamten monotherapy (MAPLE-HCM) under FDA review with PDUFA date November 14, 2026
  • Positive topline results from ACACIA-HCM (nHCM) presented; KCCQ-CSS LSM difference 3.0 (p=0.021) and pVO2 LSM difference 0.67 mL/kg/min (p=0.003)
  • Eligible to draw up to $175M from Royalty Pharma loan; up to $150M option for ulacamten pivotal trial funding
  • Omecamtiv mecarbil Phase 3 COMET-HF enrolling; ulacamten Phase 2 AMBER-HFpEF enrolling

Financial Impact

No new financial impact; reiterates ~$1.1B cash position and access to up to $325M additional capital

cashrevenue

Risk Factors

  • Regulatory risk for MAPLE-HCM sNDA and potential label restrictions
  • Commercial adoption slower than expected; competition from CAMZYOS
  • Dilution risk from potential capital raises despite existing cash and loan facilities

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-206420
Document: d124879d8k.htm0001193125-26-206420
Document: 0001193125-26-206420-index-headers.html0001193125-26-206420
Document: 0001193125-26-206420-index.html0001193125-26-206420
Document: 0001193125-26-206420.txt0001193125-26-206420

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026